Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006617 · ClinicalTrials.gov registry record · NA

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT00006617: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00006617 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006617, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if the multidrug combination of zidovudine (ZDV), lamivudine (3TC), 1592U89 (abacavir \[ABC\]), and 141W94 (amprenavir \[APV\]) is a safe and effective treatment for HIV-infected patients and if there is a reduction of active HIV in blood and other tissues. HIV infection is a life-changing illness and new HIV treatments must be tested. This study will test if a 4-drug combination will reduce HIV virus activity in blood and other tissues and if it is safe and well tolerated. Doctors also want to know if the multidrug combination is able to decrease viral activity over a long time period.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Lamivudine
  • DRUG Abacavir sulfate
  • DRUG Amprenavir

Study Locations (1)

New York

  • Aaron Diamond AIDS Res Ctr - New York

Trial Details

FieldValue
Enrollment Target 25 participants
Est. Completion 2007-06
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00006617 record still lists

NCT00006617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Zidovudine is the first listed.

NCT00006617 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00006617 about?

NCT00006617 is a clinical study titled "Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients". The purpose of this study is to see if the multidrug combination of zidovudine (ZDV), lamivudine (3TC), 1592U89 (abacavir \[ABC\]), and 141W94 (amprenavir \[APV\]) is a safe and effective treatment for HIV-infected patients and if there is a reduction of active HIV in blood and other tissues. HIV i...

What is the current status of trial NCT00006617?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. Estimated completion is 2007-06.

What conditions does trial NCT00006617 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00006617?

The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).

Who is sponsoring clinical trial NCT00006617?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006617 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00006617's enrollment target sits among peer trials

25 461st of 542 higher than 74 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Related registry views

Source: ClinicalTrials.gov NCT00006617, the US trial registry maintained by the National Library of Medicine. NCT00006617 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.